Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?

Autor: Shelly B. Hayes, Chihsiung E. Wang, Darren B. Sachs, Cecilia Chang, Allison A. Aggon, Elias Obeid, John M. Daly, Richard J. Bleicher, Gabrielle Gauvin, Elin R. Sigurdson, Nicole M. Melchior
Rok vydání: 2019
Předmět:
0301 basic medicine
Cancer Research
medicine.medical_specialty
Adjuvant chemotherapy
medicine.medical_treatment
Breast Neoplasms
Gastroenterology
lcsh:RC254-282
surgery
03 medical and health sciences
0302 clinical medicine
Breast cancer
breast cancer
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Preoperative Care
medicine
Preoperative chemotherapy
Humans
Radiology
Nuclear Medicine and imaging
Stage (cooking)
Original Research
Chemotherapy
business.industry
Endocrine therapy
Cancer
Clinical Cancer Research
Middle Aged
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Prognosis
Neoadjuvant Therapy
Radiation therapy
Survival Rate
cancer management
030104 developmental biology
Oncology
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Female
business
Follow-Up Studies
neoadjuvant chemotherapy
Zdroj: Cancer Medicine
Cancer Medicine, Vol 9, Iss 8, Pp 2742-2751 (2020)
ISSN: 2045-7634
Popis: Background/Objective Delays in times to surgery, chemotherapy, and radiotherapy impair survival in breast cancer patients. Neoadjuvant chemotherapy (NAC) confers equivalent survival to adjuvant chemotherapy (AC), but it remains unknown which approach facilitates faster initiation and completion of treatment. Methods Women ≥18 years old with nonrecurrent, noninflammatory, clinical stage I‐III breast cancer diagnosed between 2004 and 2015 who underwent both surgery and chemotherapy were reviewed from the National Cancer Database. Results Among 155 606 women overall, 28 241 patients received NAC and 127 365 patients received AC. NAC patients had higher clinical T and N stages (35.8% T3/4 vs 4.9% T3/4; 14.4% N2/3 vs 3.7% N2/3). After adjusting for stage and other factors, NAC patients had longer times to begin treatment (36.1 vs 35.4 days adjusted, P = .15), and took significantly longer to start radiotherapy (240.8 vs 218.2 days adjusted, P
This study evaluated the time to initiation and completion of treatment in breast cancer patients undergoing neoadjuvant chemotherapy (NAC) vs adjuvant chemotherapy. We found that NAC did not expedite the start or completion of treatment.
Databáze: OpenAIRE
Externí odkaz: